Jiangsu Hengrui Pharmaceuticals (HKG:1276, SHA:600276) received a drug registration certificate from China's National Medical Products Administration to market Reglitin-Metformin Tablets (I)/(II), according to a Shanghai Stock Exchange filing on Thursday.
The drug is indicated to improve glycemic control in adult patients with type 2 diabetes, who are suitable for treatment with phosphate reglitin and metformin hydrochloride.
This product is China's first independently developed fixed-dose combination formulation of a dipeptidyl peptidase-4 inhibitor with metformin, the disclosure said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。